Patient demographics
| . | Lymphoma/CLL cohort . | Healthy cohort . |
|---|---|---|
| N = 23 (%) . | N = 23 (%) . | |
| Age, y | ||
| Median (range) | 69 (30-82) | 24 (22-56) |
| Sex | ||
| Male | 10 (43) | 10 (43) |
| Female | 13 (57) | 13 (57) |
| Vaccine type | ||
| mRNA-1273 | 7 (30) | 14 (61) |
| BNT162b2 | 16 (70) | 9 (39) |
| Disease type | ||
| CLL | 14 (61) | |
| DLBCL | 3 (13) | |
| MCL | 3 (13) | |
| Follicular lymphoma | 1 (4) | |
| MZL | 1 (4) | |
| HL | 1 (4) | |
| No. of prior lines of therapy | ||
| Median (range) | 1 (0 - 3) | |
| Treatment status | ||
| Treatment naive | 6 (26) | |
| Prior treatment | 6 (26) | |
| Current treatment | 11 (48) | |
| Prior CD20 Ab therapy | ||
| Yes | 15 (65) | |
| No | 8 (35) | |
| CD20 Ab within 12 mo | ||
| Yes | ||
| Within 12 mo | 6 (26) | |
| Beyond 12 mo | 9 (39) | |
| No | 8 (35) | |
| . | Lymphoma/CLL cohort . | Healthy cohort . |
|---|---|---|
| N = 23 (%) . | N = 23 (%) . | |
| Age, y | ||
| Median (range) | 69 (30-82) | 24 (22-56) |
| Sex | ||
| Male | 10 (43) | 10 (43) |
| Female | 13 (57) | 13 (57) |
| Vaccine type | ||
| mRNA-1273 | 7 (30) | 14 (61) |
| BNT162b2 | 16 (70) | 9 (39) |
| Disease type | ||
| CLL | 14 (61) | |
| DLBCL | 3 (13) | |
| MCL | 3 (13) | |
| Follicular lymphoma | 1 (4) | |
| MZL | 1 (4) | |
| HL | 1 (4) | |
| No. of prior lines of therapy | ||
| Median (range) | 1 (0 - 3) | |
| Treatment status | ||
| Treatment naive | 6 (26) | |
| Prior treatment | 6 (26) | |
| Current treatment | 11 (48) | |
| Prior CD20 Ab therapy | ||
| Yes | 15 (65) | |
| No | 8 (35) | |
| CD20 Ab within 12 mo | ||
| Yes | ||
| Within 12 mo | 6 (26) | |
| Beyond 12 mo | 9 (39) | |
| No | 8 (35) | |